Localisation and Technology Transfer: Certain Costs and Uncertain Benefits

1. Key takeaways

The benefits of localised manufacturing in Saudi Arabia fall into two categories. One category is support the SFDA has written explicitly into its documents and that can be used immediately — 4 items: the call centre 19999, the mailbox md.rs@sfda.gov.sa, meetings with the SFDA technical team, and seminars, all free of charge. The other category is policy orientation at the industrial and procurement level, whose specific terms, quotas and conditions of application must follow the written documents of the Saudi competent authorities; any fiscal subsidy, tax incentive or preferential-procurement promise not confirmed in writing should never enter the investment model. The compliance-cost side is certain: whichever of the MDS-G011 paths is chosen, a manufacturer licence issued under MDS-REQ 9 and an ISO 13485:2016 certificate issued by an SFDA-recognised conformity assessment body (CAB) are required, and changes must be notified under MDS-G12. Settle the certain costs first, then discuss the uncertain benefits. Regulatory information verified as of 29 October 2026.

• Certain benefits: four free SFDA support channels — call 19999, md.rs@sfda.gov.sa, technical-team meetings, seminars.
• Policy-level benefits need written confirmation of terms, quotas and conditions before entering any financial model.
• Certain costs: MDS-REQ 9 manufacturer licence, SFDA-recognised CAB’s ISO 13485:2016 certificate, and MDS-G12 change notification.

2. Legal basis

The following instruments set out the technical-support commitments, the statutory definitions, and the licence and QMS obligations that constitute the certain cost side of localisation.

3. Expert insights

1. Path selection must be completed before the plant lands

The typical order when companies make localisation decisions is: look at land prices, labour and supply chain first, find a suitable industrial park, then consider how the registration will be handled. Under the Saudi system that order must be reversed. MDS-G011 splits in-Kingdom manufacturing into full manufacturing, branch manufacturing and contract manufacturing — 3 paths — each pointing to a different MDMA holder and a different QMS coverage. If the assembly workshop is built first and it then turns out that under Law M/54 Article 1 packaging and labelling also count as manufacturing, that workshop becomes the manufacturer on the MDMA outright, and the licence holder, the liability bearer and the subsequent change obligations all change with it. The plant is a one-off investment, and entity determination is a step that is hard to walk back — especially once transaction pricing between the onshore and offshore entities has been set and transferred and cannot easily be restructured. Walking the path on paper first and then looking at land costs far less.

2. Technology transfer usually fails in the documents, not on the line

Once equipment is installed and staff trained, the factory looks able to produce. From the SFDA inspection perspective, however, being able to make the product and being able to make it consistently in the approved state are two different things. The former rests on equipment; the latter rests on the system: the parent company’s product-realisation process must be transcribed completely into records for the new site — product-realisation planning, process flow charts, process validation records for critical steps, inspection procedures and incoming acceptance criteria for raw materials, control and traceability procedures for nonconforming product, and the audit arrangements needed to bring the new site into the ISO 13485:2016 certificate scope. Another underrated element is the depth of design-development file transfer: new sites often receive only drawings and the final work instructions, without the structured design history and the background of changes, so change management breaks its chain from day one. In technology-transfer coaching GRZAN normally builds two comparison lists — a document transfer list and a process transfer list — and aligns them item by item before any equipment moves.

3. Write the localisation benefits as verifiable line items, not as expectations

What the SFDA explicitly promises is four items of free technical support, resources that can be used immediately: calling 19999 or writing to md.rs@sfda.gov.sa to ask about the concrete execution approach before drafting a technical plan is far cheaper than guessing the tolerance afterwards; applying for a face-to-face meeting with the technical team and attending its seminars are also on the official list. As for local industrial support, financing or tax arrangements, GRZAN’s advice is to require written documents stating the conditions of application, duration and approving body before anything enters the financial model; verbal promises without written basis are treated as zero across the board. The reason is simple: the MDMA will be issued in the name of the in-Kingdom manufacturer, and subsequent inspections, changes and post-market obligations are all borne by that entity; if certain compliance costs are covered by unrealisable benefits, the accounts show a long-term gap. The details of the three manufacturing paths are in https://www.grzan.cn/regulations/saudi/mds-g011-manufacturing-paths-17 ; the handling of MDMA attribution and authorised-representative changes is in https://www.grzan.cn/regulations/saudi/authorized-representative-transfer-and-mdma-change-33 .

4. Practical recommendations

• At project initiation, run the path deduction first (full / branch / contract manufacturing), write the conclusion into the feasibility report, and only then discuss site selection.
• Build the document transfer list and the process transfer list as two comparison tables and verify transfer completion item by item.
• Schedule the ISO 13485:2016 audit early to bring the new site into certificate scope, and back-plan the audit timing into the production start plan.
• Apply for the manufacturer licence under MDS-REQ 9 ahead of time, noting that obtaining it is one of the preconditions for MDMA issuance.
• For every process, site or supplier change, make the MDS-G12 judgement first and act afterwards, avoiding unnotified changes.
• Use the official free channels: archive the reply references from calls to 19999 and emails to md.rs@sfda.gov.sa, and request a meeting with the technical team when necessary.
• Land every policy-side benefit on a written document; nothing without written basis enters the financial model.

5. Verification checklist

• □ The path deduction is complete and the in-Kingdom entity’s legal status is determined in writing
• □ The manufacturer licence application (MDS-REQ 9) has started or the licence is held
• □ The ISO 13485:2016 certificate covers the new in-Kingdom site and its activities
• □ The document transfer list and the process transfer list are aligned item by item and signed off
• □ Process validation (critical steps) is completed and recorded at the new site
• □ Supplier and incoming-inspection standards are localised and consistent with the parent company’s file versions
• □ Change management procedures are embedded per MDS-G12 in the local plant’s daily operations
• □ All policy-side benefits are supported by written documents; nothing was booked on verbal promises
• □ SFDA communication records (19999 call records, emails, meeting minutes) are archived with reference numbers

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team manages SFDA MDMA applications across classes, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzan.com